✦ LIBER ✦

Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

✍ Scribed by Langenberg, Marlies H.G.; Witteveen, Petronella O.; Lankheet, Nienke A.G.; Roodhart, Jeanine M.L.; Rosing, Hilde; van den Heuvel, Ingeborg J.G.M.; Beijnen, Jos H.; Voest, Emile E.

Book ID: 122123455
Publisher: Neoplasia Press
Year: 2010
Tongue: English
Weight: 660 KB
Volume: 12
Category: Article
ISSN: 1522-8002
DOI: 10.1593/neo.91864

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I dose escalation and pharmacoki

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

✍ E. Gabriela Chiorean; Srikar Malireddy; Anne E. Younger; David R. Jones; Mary-Ja 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

Phase 1-2 trial of PTK787/ZK222584 combi

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma : Implication for antiangiogenic approach to hepatocellular carcinoma

✍ Thomas Yau; Pierre Chan; Roberta Pang; Kelvin Ng; S. T. Fan; Ronnie T. Poon 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

## Abstract ## BACKGROUND: This phase 1‐2 trial assessed the efficacy and tolerability of an oral angiogenesis inhibitor—PTK787/ZK222584 (PTK)—in combination with intravenous doxorubicin for the treatment of advanced hepatocellular carcinoma (HCC) patients. ## METHODS: In phase 1, advanced HCC p

949 POSTER Antiangiogenesis as new treat

949 POSTER Antiangiogenesis as new treatment modality in ovarian cancer: a phase Ib, open label, safety and pharmacokinetics (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Phase I pharmacokinetic and pharmacodyna

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors

✍ Simonelli, Matteo; Zucali, Paolo A.; Lorenzi, Elena; Rubino, Luca; De Vincenzo, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 585 KB

87 Inhibition of Autophagy: a Phase 1 Sa

87 Inhibition of Autophagy: a Phase 1 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor, Vorinostat, in Patients with Advanced Solid Tumors

✍ Mahalingam, D.; Mita, M.; Sarantopoulos, J.; Amaravadi, R.; Davis, L.; Mita, A.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB